HeartSciences (NASDAQ:HSCS) Announces Quarterly Earnings Results

HeartSciences (NASDAQ:HSCS) posted its quarterly earnings data on Monday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14), FiscalAI reports. The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.10 million.

HeartSciences Stock Down 2.8%

Shares of HSCS traded down $0.10 during midday trading on Tuesday, hitting $3.44. The company’s stock had a trading volume of 65,665 shares, compared to its average volume of 843,966. HeartSciences has a one year low of $1.63 and a one year high of $4.35. The stock has a market capitalization of $13.41 million, a price-to-earnings ratio of -0.87 and a beta of 1.85. The company’s fifty day simple moving average is $2.69 and its two-hundred day simple moving average is $2.39.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HSCS shares. Wall Street Zen raised HeartSciences to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.